Safety and Efficacy of P-ESWL and ERCP

Naval Military Medical University

Status: Completed

Conditions: Pancreatic Duct Stone

Treatments: Procedure: pancreatic extracorporeal shock wave lithotripsy

Study type: Observational

Funder types: Other

Identifiers

NCT05916547

SEEPS

Details and patient eligibility

About

To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP), define the grading criteria of adverse events after P-ESWL and ERCP, and analyze the efficacy of P-ESWL and ERCP, which will provide evidence-based medical evidence to guide physicians' clinical practice.

Full description

Currently, pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP) has become the preferred treatment for pancreatic duct stones. Although some studies had confirmed the safety and efficacy of P-ESWL and ERCP, the sample size were small and the follow-up period were short. Therefore, investigators designed this study with a large sample and a long follow-up period to clarify the efficacy and safety of P-ESWL and ERCP, so as to guide clinical work, standardize the diagnosis and treatment process of adverse events.

Enrollment: 2,071 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients hospitalized in Changhai Hospital from 2011.03.01 to 2018.06.30.
• Painful patients with chronic pancreatitis.
• Patients who completed pancreatic extracorporeal shock wave lithotripsy.

Exclusion criteria

• Patients who diagnosed pancreatic cancer within 2 years after diagnosing chronic pancreatitis.
• Patients who refused to participate in the study.